Question explored with the scientific record
Is Ivermectin a good cancer fighter?
Ivermectin kills cancer cells in lab dishes and mice. Whether it helps a real patient is unproven.
The retrieved studies are all lab work: esophageal cancer cells and mice [1], glioma cells [5][7], breast cancer cells [6], and a platelet-coated nanocrystal built to ferry the drug to tumors in mice [3]. One review lists ivermectin among repurposed drugs with "limited clinical contexts" [4]. That is the ceiling of what this search shows. No human cancer trial with survival or tumor-shrinkage outcomes appears here. A cell dying in a dish at 5 to 20 micromolar [1][7] tells you nothing about whether an oral dose reaches that concentration inside a tumor, or whether it shrinks a tumor in a person.
The safety side matters too. A 2026 review of adverse event reports found signals for nerve and brain problems, including encephalopathy [2]. Those reports are voluntary and cannot prove cause [2], but they are a warning, not a clearance.
| Model | Ivermectin effect | What it proves |
|---|---|---|
| Esophageal cells, mice | Tumor growth inhibited [1] | Lab only |
| Glioma cells, mice | Growth and blood vessel formation inhibited [7] | Lab only |
| Breast cells | Cell death at 2 to 32 micromolar [6] | Lab only |
| Human cancer patients | No outcome data in this search | Nothing yet |
The honest gap: this retrieval cannot see whether any human trial exists, positive or negative. What would settle it is a randomized trial in cancer patients measuring tumor response and survival, not cell death.
My call: not a proven cancer treatment, and taking it instead of standard care is a gamble with no human payoff shown. Confidence: moderate that the human evidence is absent from this search; low on any benefit.
Sources used 7
-
Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
Ivermectin inhibits ESCC proliferation in vitro and in vivo by inducing mitochondrial dysfunction, ROS accumulation, NF-κB inhibition, and apoptosis via the mitochondrial pathway.
DOI: 10.1186/s12885-021-09021-x -
Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis
FAERS pharmacovigilance found ivermectin safety signals in eye, nervous system, and general disorders, with network toxicology nominating EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2 as candidate toxicity targets.
DOI: 10.3389/fcimb.2026.1938550 -
Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management
The study develops biomimetic platelet-membrane camouflaged ivermectin nanocrystals (PMV/Ivm-NC) using a sonoprecipitation method and platelet membrane coating to achieve targeted tumor homing, immunogenic cancer cell death, and enhanced antitumor/antimetastatic effects against …
DOI: 10.1007/s13346-025-02032-2 -
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress
Ivermectin, a repurposed antiparasitic, inhibits glioblastoma cell growth and angiogenesis by inducing mitochondrial dysfunction and oxidative stress, while concurrently suppressing the Akt/mTOR signaling axis in tumor and endothelial cells, with supporting in vivo xenograft dat…
DOI: 10.1016/j.bbrc.2016.10.064